Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging

Study Objective To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole. Design Single‐center, retrospective cohort study. Setting Large community teaching hospital. Patients A total of 568 adults who underwent sing...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2017-06, Vol.37 (6), p.657-661
Main Authors: Amer, Kallie A., Hurren, Jeff R., Edwin, Stephanie B., Cohen, Gerald
Format: Article
Language:English
Subjects:
Adenosine A2 Receptor Agonists - adverse effects
Adenosine A2 Receptor Agonists - economics
Aged
Aminophylline
cardiac stress test
Cohort Studies
Cost control
Cost-Benefit Analysis - methods
Dipyridamole
Dipyridamole - adverse effects
Dipyridamole - economics
Dyspnea - chemically induced
Dyspnea - economics
Electronic medical records
Emission measurements
Female
Gastrointestinal Diseases - chemically induced
Gastrointestinal Diseases - economics
Heart diseases
Heart Diseases - diagnostic imaging
Heart Diseases - economics
Humans
Male
Medical imaging
Middle Aged
myocardial perfusion imaging
Myocardial Perfusion Imaging - adverse effects
Myocardial Perfusion Imaging - economics
Myocardial Perfusion Imaging - methods
Perfusion
Purines - adverse effects
Purines - economics
Pyrazoles - adverse effects
Pyrazoles - economics
regadenoson
Retrospective Studies
Vasodilator Agents - adverse effects
Vasodilator Agents - economics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study Objective To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole. Design Single‐center, retrospective cohort study. Setting Large community teaching hospital. Patients A total of 568 adults who underwent single‐photon emission tomography MPI with either regadenoson (284 patients) or dipyridamole (284 patients) as a vasodilator agent, following an institution conversion from regadenoson to dipyridamole in the MPI protocol on July 15, 2013, for cost‐saving purposes. Measurements and Main Results Data were collected from the patients’ electronic medical records. The primary endpoint was the composite occurrence of any documented adverse event in each group. Secondary endpoints were individual components of the primary endpoint, reason for termination of the MPI examination (protocol completion or premature end due to an adverse event), use of an interventional agent to an treat adverse event, and cost‐related outcomes. A higher proportion of patients in the regadenoson group experienced an adverse event than those who received dipyridamole (84.9% vs 56.7%, p
ISSN:0277-0008
1875-9114
DOI:10.1002/phar.1940